This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ORIX Ventures Announces $10 Million Growth Capital Commitment To Talyst

ORIX Ventures announces the closing of a $10 million growth capital commitment to Talyst. The funding is structured to provide immediate growth capital to the company. Initial proceeds will be used to support Talyst’s expansion into the long-term care and correctional markets, as well as its plans to achieve greater penetration in acute-care market.

Located in Seattle, Washington, Talyst is a leader in pharmacy automation providing enterprise-wide medication management across entire health systems. Its solutions offer greater inventory control, enhanced workflow efficiency and improved patient safety. Talyst was founded in 2002 to provide easy-to-use, automated medication management systems to acute-care hospital pharmacies.

The funding of Talyst underscores ORIX Ventures’ intent to forge partnerships with fast-growing, later stage companies, as well as its particular interest in health care companies.

“We believe this funding from ORIX Ventures validates the market leadership and growth potential of Talyst,” said CEO Carla Corkern. “Having a strong partner, such as ORIX Ventures, which can support the financial needs of Talyst throughout our expansion gives us a competitive edge by enabling us to respond quickly to marketplace opportunities.”

David Orlandella, a Principal at ORIX Ventures, commented, “We are pleased to partner with Talyst’s management team which has demonstrated an impressive ability to strategically scale the company and build a leading technology company in the pharmacy automation space.”

About ORIX Ventures

ORIX Ventures provides customized financial solutions up to $50 million in capital per transaction to mid- and late-stage companies which have established customers and run-rate revenues of $10 million or greater. Since its inception in 2001, ORIX Ventures has invested in more than 100 growth companies throughout the U.S. and Canada. www.orixventures.com. ORIX USA is a Dallas, Texas-based financial services and investment firm with more than 1,400 employees and primary offices in Dallas, New York, Los Angeles, Columbus and Minneapolis. ORIX USA holds approximately $6 billion of assets and manages through various subsidiaries an additional $25 billion. www.orix.com. ORIX USA is a wholly owned subsidiary of ORIX Corporation, a Tokyo-based, publicly owned international financial services company with operations in 27 countries worldwide. ORIX Corporation is listed on the Tokyo (8591) and New York Stock Exchanges (IX).

Follow us on Twitter: @orixventures

About Talyst

Talyst is a leader in pharmacy automation and engineers the safer pharmacy. The company’s solutions provide enterprise-wide medication management across entire health systems to offer greater inventory control, enhanced workflow efficiency, and improved patient safety. As of 2012, Talyst has installed automated systems in more than 600 integrated healthcare systems, acute-care hospitals, long-term care facilities, and correctional institutions. Talyst offers a powerful software platform with a suite of hardware components to meet specific needs of health care providers. Visit Talyst at www.talyst.com.



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs